Q3 2026 LeMaitre Vascular, Inc. Earnings Conference Call - LEMAITRE VASCULAR INC

Explicit Guidance:

• FY2026 Organic Sales Growth: Reiterated at 11%.
• FY2026 Reported Sales Growth: Guidance of $275.8 million (reflects Euro/USD rate of 1.12 vs. 1.15 in August).
• FY2026 Operating Margin: Full-year operating income of $75.4 million, resulting in a 27% operating margin.
• FY2026 Gross Margin: Updated to 72.1% for the full year (30 basis points reduction from prior guidance; 170 bps improvement vs. adjusted 2025).
• FY2026 EPS: Updated to $2.80 (fully diluted), representing 18% growth from adjusted 2025.
• FY2026 Tax Rate/Other: No specific guidance on tax rate, share count, or dividends; guidance includes modest 2026 impact of B. Braun acquisition.
• Q4 FY2026 Specifics: Expects to record approx. $150,000 in revenue from direct B. Braun sales (no net operating income impact); FX impact estimated at $450,000 lost in USD value since August.

Business-Segment Outlook:

• Autograph (Biologics):
  • International Expansion: Targeting approvals in Korea, India, and Japan (PMDA application planned Q4 2026 for 2029/2030 approval). Currently approved in 60 countries.
  • Product Innovation: Submitting for U.S. and C.E. Mark long-tube approval in Q4 2026; first sales expected in H2 2027.
  • Strategic Claims: Evaluating the potential for a 5-year clinical trial to support FDA "Quick-Stick" claims for AV Access (no decision made yet).
  • FY2026 Outlook: Full-year sales expected >$11 million (Q3 international sales were $3 million).
• RestoreFlow Allografts:
  • Geographic Expansion: Targeting approvals in Holland, Ireland, Spain, and Switzerland in 2027. Currently approved in 6 countries.
  • Capacity & Operations: Plan to close Chicago (Fox River Grove) facility and fully transfer production to Burlington by year-end 2026.
  • Growth: Cardiac tissue segment grew 65% YoY in Q3; backlog constraints noted in processing/clearance rather than supply sourcing.
• B. Braun Acquired Portfolio:
  • Transition Period: Commercial transition expected to take 18–24 months. B. Braun to continue manufacturing under a four-year supply agreement.
  • Revenue Impact: Anticipated breakage of 10–15% in Year 1, followed by recovery; products expected to grow at similar margin profile (40–50% gross margin) to existing polyester grafts.
• Product Discontinuation: FASTIP discontinued; one-time inventory reserve impact noted.

Market and Competitive Outlook:

• Share Position: Acquisition targets making LeMay #3 in worldwide market share (ex-Japan) for polyester grafts.
• Pricing Strategy: Strong ASP growth continues to drive margin expansion; price increases expected to flow through despite inflation.
• Competitive Landscape:
  • Polyester Grafts: B. Braun products not approved for U.S. market; company remains in a duopoly (Gore, Terumo) for U.S. polyester grafts and sees no need to enter.
  • Biologics: Anticipates "cannibalization" of OmniFlow (sheep graft) usage as new long Autograph products launch, viewing it as product improvement rather than loss.
• Demand Trends: High demand for cardiac allografts exceeding current processing capacity; demand for long leg bypasses in Europe driving need for longer graft sizes.

Macro / Industry Outlook:

• FX Rates: Strengthening U.S. dollar (Euro at 1.12 vs. 1.15) negatively impacting reported revenue guidance ($450k impact).
• Regulatory: FDA re-inspection of New Jersey facility likely in 2027; current inspections have not disrupted production or invoicing.
• Healthcare Policy: Management states U.S. procedure volumes (limb salvage, dialysis access) are resilient to Medicaid/ACA fluctuations and DRG changes; no significant negative impact from recent election results on procedure volumes anticipated.
• Geopolitical: No specific disruptions identified in the Middle East or Europe (e.g., French riots) affecting Q3 results; FX noted as primary headwind for EMEA reported growth.

Strategic Initiatives:

• Acquisitions:
  • B. Braun Portfolio: Acquired October 2026 ($19.2M total: $16.6M initial, $2.6M deferred); integration of manufacturing to Burlington expected to complete by Year 3/Late Year 2.
  • M&A Strategy: Continues acquisitive strategy; recruiting senior business development executives following Dave Roberts' departure.
• Commercial Expansion:
  • Sales Force: Rep count ended Q3 at 171; projected range 172–178 for FY2026.
  • Geographic Infrastructure: Opening Polish office/warehouse in Q1 2027; Malaysian office/warehouses in 2027; total of 7+ new/larger international warehouses planned for 2026–2027.
  • Manufacturing: Burlington facility expansion (30,000 sq ft) to be occupied in July 2027 for consolidation and acquisition integration.
• Personnel: Transition of Global Head of Marketing to Tarek Pachuca (ex-Terumo Aortic); Dave Roberts stepping down as President after 30 years.

Risks and Headwinds to Outlook:

• Regulatory/Capacity: Potential production backorders during the B. Braun transition; processing bottlenecks for RestoreFlow allografts slowing time-to-revenue.
• Commercial Execution: Risk of 10–15% customer breakage in Year 1 of B. Braun integration due to bundling disruptions; reliance on customer willingness to re-bundle.
• FX Volatility: Continued strengthening of the U.S. dollar vs. Euro and other currencies could reduce reported revenue and operating leverage.
• One-Time Costs: Inventory reserve for discontinued FASTIP ($0.5M) and transfer costs for RestoreFlow impacting gross margin timing.
• Personnel Transition: Key leadership change (President departure) and integration risks associated with new senior hires.

Management Tone on the Future:

• Confidence Level: Confident in long-term growth trajectory (5-year CAGR of 11–12%); optimistic about the strategic fit of B. Braun assets and international expansion.
• Cautions: Hesitant to provide FY2027 guidance due to uncertainty surrounding the B. Braun transition timeline ("uneducated" on specific 2027 numbers until Q4 2026 data is available); acknowledges "good news/bad news" dynamic regarding allograft supply vs. demand.
• Strategic Focus: Emphasizes "no-backorder" commitment as a key differentiator for winning back customers post-transition.

Miscellaneous:

• Timeline Clarification: Q3 2026 was the first full quarter for Autograph comp, providing a clearer baseline for growth.
• Market Entry Logic: B. Braun revenue in specific countries (e.g., Slovakia) is being used to justify opening direct sales operations in neighboring regions (e.g., Poland) previously considered untapped.
• Financial Metrics: Q3 Operating Margin 26%; ROIC 27%; Free Cash Flow $19.7 million (up $6M sequentially).